These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24643839)

  • 61. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of appropriate antimicrobial therapy for patients with severe sepsis and septic shock--a quality improvement study.
    Yokota PK; Marra AR; Martino MD; Victor ES; Durão MS; Edmond MB; dos Santos OF
    PLoS One; 2014; 9(11):e104475. PubMed ID: 25375775
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Lipman J
    Clin Infect Dis; 2013 Jan; 56(2):236-44. PubMed ID: 23074313
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.
    Nobre V; Harbarth S; Graf JD; Rohner P; Pugin J
    Am J Respir Crit Care Med; 2008 Mar; 177(5):498-505. PubMed ID: 18096708
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Personalised antibiotic therapy in a surgical intensive care unit overview of current knowledge and the results of an observational kinetic study].
    Kaška M; Martinková J; Havel E; Kočí J; Fousková A; Solichová D; Kujovská L; Selke-Krulichová I; Práznovec I; Salavec V
    Rozhl Chir; 2014 Sep; 93(9):456-62. PubMed ID: 25301344
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.
    Andriolo BN; Andriolo RB; Salomão R; Atallah ÁN
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010959. PubMed ID: 28099689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis.
    Lutsar I; Metsvaht T
    Curr Opin Infect Dis; 2010 Jun; 23(3):201-7. PubMed ID: 20179595
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetic-pharmacodynamic modelling of antibiotic therapy in severe sepsis.
    Duszyńska W
    Anaesthesiol Intensive Ther; 2012; 44(3):158-64. PubMed ID: 23110294
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of dosage schedule of antibiotics on the treatment of serious infections.
    Bakker-Woudenberg IA; Roosendaal R
    Intensive Care Med; 1990; 16 Suppl 3():S229-34. PubMed ID: 2289996
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Antibiotic therapy: impact and resistance].
    Weiler S; Corti N
    Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):167-74. PubMed ID: 24696278
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock.
    Vazquez-Guillamet C; Scolari M; Zilberberg MD; Shorr AF; Micek ST; Kollef M
    Crit Care Med; 2014 Nov; 42(11):2342-9. PubMed ID: 25072764
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.
    Udy AA; Dulhunty JM; Roberts JA; Davis JS; Webb SAR; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J; ;
    Int J Antimicrob Agents; 2017 May; 49(5):624-630. PubMed ID: 28286115
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
    Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetic issues for antibiotics in the critically ill patient.
    Roberts JA; Lipman J
    Crit Care Med; 2009 Mar; 37(3):840-51; quiz 859. PubMed ID: 19237886
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Beta lactam antibiotics and the question of dose regimen for severe infection. Prolonged infusion theoretically appealing--yet no evidence of clinical benefit].
    Leander G; Eliasson E; Hanberger H; Giske C
    Lakartidningen; 2015 Mar; 112():. PubMed ID: 25803536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.